Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Is nintedanib safe, effective in patients with early-stage IPF?
24 Nov 2023
bởiStephen Padilla
Results of nintedanib use in patients with early-stage idiopathic pulmonary fibrosis (IPF) show a stable change in forced vital capacity (FVC) and a gradual decline in diffusing capacity of the lungs for carbon monoxide (DLCO) at week 52, according to an ongoing study presented at APSR 2023. In addition, treatment discontinuation is comparable to that in previous clinical trials.
24 Nov 2023

Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023
bởiAudrey Abella
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.
24 Nov 2023







